In CML patients, the BCR::ABL1 quantification in peripheral blood cells at the time of diagnosis is set as 100%, and the subsequent quantifications are expressed in percentage by the BCR::ABL1/ABL1 ratio. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.